On February 20, the investment community reported that Shengzhi Runhe (Beijing) Biotechnology *** hereinafter referred to as "Shengzhi Runhe").Completed the Pre-A round of financing of tens of millions of yuan; This round of financing is exclusively invested by Jinding Capital. The financing funds will be used for the construction of production lines and replenishment of liquidity.
Founded in 2021, the company focuses on the R&D and application of regenerative biomaterials, adheres to the concept of "science and technology leading, perfection and beauty", has been deeply engaged in regenerative biomaterials for more than ten years, gathered a team of top domestic scientists in the biological field, formed a number of its own intellectual property rights, and is committed to becoming a technology pioneer and core service provider in the field of anti-aging of regenerative biomaterials. The company has successfully passed the identification of national high-tech enterprises and obtained the recognition of "innovative" small and medium-sized enterprises in Beijing. At present, Shengzhi Runhe has mastered the preparation technology of ECM for a variety of tissues, among which the omentum ECM neck pattern filling product has carried out clinical trials in 4 tertiary hospitals including Beijing Badachu, and all subjects have entered the observation period, which is the first ECM medical aesthetic injection product to enter the clinical trial in China.
Ms. Xu Shaomei, founder & CEO of Shengzhi Runhe, said:In the past few years, Runhe has made great efforts to explore, explore technical paths, break through technological innovation, and realize the leading advantages of subdivided track technology. In the next 3 years, Runhe will fully enter the fast lane of development, adhere to market-oriented, customer-centric, continue to optimize product performance, enrich product pipelines, build a marketing and marketing system, realize the dual drive and double pull of technology and market, and implement the technical advantages of recycled materials and broad market application prospects.
The person in charge of the big health business department of Jinding Capital saidThis investment relies on Marubeni Jinding Industry**. Jinding Capital has been paying attention to investment opportunities in new materials for medical aesthetic injections. ECM is a real regenerative material, a complex 3D network synthesized by cells and secreted to the outside of cells, which acts on cells and on cells. ECM and cells together constitute tissues and organs, and act as a signaling platform for cell-cell interactions. It can provide physical support for the integrity of cells, tissues and organs; Optimize the extracellular microenvironment to improve cell viability and promote new cell generation; It has good tissue repair and guided regeneration ability.